|Systematic (IUPAC) name|
|Licence data||US FDA:|
|Pregnancy cat.||B3 (AU) B (US)|
|Legal status||℞-only (US)|
|Protein binding||Negligible (<4.0%)|
|Mol. mass||207.224 g/mol|
|Melt. point||114 °C (237 °F)|
|(what is this?)|
Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to break down complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.
Miglitol, and other structurally-related iminosugars, inhibit glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.
Recent study on rats by shrivastva et al. showed that miglitol has antioxidant effect and hypocholesterolemic effect.
- "Migliotl: MedlinePlus Drug Information". MedlinePlus. National Institudes of Health. 1 September 2010. Retrieved 13 April 2013.
- "Glyset (miglitol) tablets label - Accessdata FDA". Drugs@FDA. U.S. Food and Drug Administration. August 2012. Retrieved 13 April 2013.
- Shrivastava, Atul; Chaturvedi, Upma; Singh, Shiv Vardan; Saxena, Jitendra Kumar; Bhatia, Gitika (2013). "Lipid Lowering and Antioxidant Effect of Miglitol in Triton Treated Hyperlipidemic and High Fat Diet Induced Obese Rats". Lipids 48 (6): 597–607. doi:10.1007/s11745-012-3753-3. PMID 23334955.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|